$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

$iova Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417040380 Filed on August 03, 2017

Income Statement

Concept	2017 Q2	2016 Q4	2016 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.930M	$5.090M	$7.260M
YoY Change	-45.87%	-0.78%	90.05%
% of Gross Profit
Research & Development	$18.65M	$10.84M	$4.463M
YoY Change	317.81%	226.51%	10.06%
% of Gross Profit
Depreciation & Amortization	$240.0K	$290.0K	$270.0K
YoY Change	-11.11%	-6.45%	12.5%
% of Gross Profit
Operating Expenses	$23.58M	$15.92M	$11.73M
YoY Change	101.08%	88.4%	82.1%
Operating Profit	-$23.58M		-$11.73M
YoY Change	101.08%		82.1%
Interest Expense	$200.0K	$230.0K	$160.0K
YoY Change	25.0%	187.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$23.38M	-$15.69M	-$11.56M
YoY Change	102.25%	87.23%	81.48%
Income Tax
% Of Pretax Income
Net Earnings	-$23.38M	-$15.69M	-$11.56M
YoY Change	102.17%	87.67%	81.61%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$374.3K	-$252.3K	-$226.3K
COMMON SHARES
Basic Shares Outstanding	62.35M shares		48.55M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2016 Q4	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$129.0M	$166.5M	$191.6M
YoY Change	-32.67%	60.56%	70.61%
Cash & Equivalents	$114.3M	$106.7M	$121.0M
Short-Term Investments	$14.70M	$59.80M	$70.60M
Other Short-Term Assets	$6.400M	$3.000M	$800.0K
YoY Change	700.0%	900.0%	100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$135.4M	$169.5M	$192.4M
YoY Change	-29.59%	63.03%	70.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.578M	$2.374M	$1.192M
YoY Change	116.28%	41.65%	-41.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00
YoY Change
Total Long-Term Assets	$2.578M	$2.374M	$1.192M
YoY Change	116.28%	41.65%	-41.14%
TOTAL ASSETS
Total Short-Term Assets	$135.4M	$169.5M	$192.4M
Total Long-Term Assets	$2.578M	$2.374M	$1.192M
Total Assets	$138.0M	$171.9M	$193.5M
YoY Change	-28.69%	62.69%	68.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.695M	$863.0K	$725.0K
YoY Change	409.66%	-9.92%	-37.33%
Accrued Expenses	$5.165M	$4.105M	$3.881M
YoY Change	33.08%	510.86%	522.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.860M	$4.968M	$4.606M
YoY Change	92.36%	204.79%	146.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.860M	$4.968M	$4.606M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$8.900M	$5.000M	$4.600M
YoY Change	93.48%	212.5%	142.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$201.2M	-$157.1M	-$122.7M
YoY Change	64.0%	50.75%	39.04%
Common Stock	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	50.0%	52.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$129.2M	$166.9M	$188.9M
YoY Change
Total Liabilities & Shareholders Equity	$138.0M	$171.9M	$193.5M
YoY Change	-28.69%	62.69%	68.68%

Cashflow Statement

Concept	2017 Q2	2016 Q4	2016 Q2
OPERATING ACTIVITIES
Net Income	-$23.38M	-$15.69M	-$11.56M
YoY Change	102.17%	87.67%	81.61%
Depreciation, Depletion And Amortization	$240.0K	$290.0K	$270.0K
YoY Change	-11.11%	-6.45%	12.5%
Cash From Operating Activities	-$17.50M	-$12.16M	-$3.750M
YoY Change	366.67%	84.8%	-16.67%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$740.0K	-$60.00K
YoY Change	-66.67%	393.33%	-57.14%
Acquisitions
YoY Change
Other Investing Activities	$25.36M	$26.51M	-$10.34M
YoY Change	-345.26%	-348.45%	-89.64%
Cash From Investing Activities	$25.33M	$25.76M	-$10.40M
YoY Change	-343.56%	-338.08%	-89.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-650.0K	210.0K	96.19M
YoY Change	-100.68%	-25.0%	1596.47%
NET CHANGE
Cash From Operating Activities	-17.50M	-12.16M	-3.750M
Cash From Investing Activities	25.33M	25.76M	-10.40M
Cash From Financing Activities	-650.0K	210.0K	96.19M
Net Change In Cash	7.180M	13.81M	82.04M
YoY Change	-91.25%	-180.67%	-183.1%
FREE CASH FLOW
Cash From Operating Activities	-$17.50M	-$12.16M	-$3.750M
Capital Expenditures	-$20.00K	-$740.0K	-$60.00K
Free Cash Flow	-$17.48M	-$11.42M	-$3.690M
YoY Change	373.71%	77.6%	-15.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	59753000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6417000	USD
CY2017Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	14732000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8860000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	29000	USD
CY2017Q2	us-gaap	Revenues Revenues	0	USD
CY2016Q2	us-gaap	Revenues Revenues	0	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19653000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4463000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	23581000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	11727000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23581000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11727000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	204000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	164000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	330318000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201177000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157116000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	129152000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	166918000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138012000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	171886000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	135434000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2578000	USD
CY2017Q2	us-gaap	Assets Assets	138012000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3695000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5165000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4968000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	323994000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	621000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-23377000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-11563000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62457	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	51082	shares
CY2016	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	61000	USD
CY2016	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	32000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2545000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5123000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1581000	USD
CY2017Q2	iova	Legal And Related Services Current LegalAndRelatedServicesCurrent	898000	USD
CY2017Q2	iova	Clinical Related Expenses Current ClinicalRelatedExpensesCurrent	1066000	USD
CY2017Q2	iova	Manufacturing Related Expenses Current ManufacturingRelatedExpensesCurrent	1004000	USD
CY2017Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	485000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	87000	USD
CY2016Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	90399000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Revenues Revenues	0	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7264000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3928000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-29000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44090000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18447000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6589000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7136000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2987000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-233000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1060000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3209000	USD
	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	1000	USD
	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	1000	USD
CY2017Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	90921000	USD
CY2016Q4	us-gaap	Trading Securities Cost TradingSecuritiesCost	90370000	USD
CY2017Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	14732000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2081000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4455000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	505000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8300000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	68340000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	67881000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56000	USD
	iova	Unrealized Gain Loss On Shortterm Investments UnrealizedGainLossOnShorttermInvestments	30000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120966000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33587000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	87379000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	96194000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	237000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-515000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	540000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	464000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3375000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-36299000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	44955000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	823000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	44132000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	250000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	646000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-265000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7568000	USD
	iova	Unrealized Gain Loss On Shortterm Investments UnrealizedGainLossOnShorttermInvestments	-29000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	37000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1161000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	349000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	iova	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	0	USD
	iova	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	-155000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	129000000	USD
CY2017Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14732000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	59753000	USD
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	3293000	USD
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	5357000	USD
CY2017Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	14732000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	59753000	USD
CY2017Q2	us-gaap	Trading Securities Cost TradingSecuritiesCost	90921000	USD
CY2017Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1625000	USD
CY2016Q4	iova	Legal And Related Services Current LegalAndRelatedServicesCurrent	927000	USD
CY2016Q4	iova	Clinical Related Expenses Current ClinicalRelatedExpensesCurrent	614000	USD
CY2016Q4	iova	Manufacturing Related Expenses Current ManufacturingRelatedExpensesCurrent	437000	USD
CY2017Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2016Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	422000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	124000	USD
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	23300000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7084	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	4167	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2917	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.53
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.4
CY2016Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	500000	USD
	iova	Number Of Share Options Or Share Units Exercised During Current Period NumberOfShareOptionsOrShareUnitsExercisedDuringCurrentPeriod	128500	shares
	iova	Common Stock Registered For Resale CommonStockRegisteredForResale	128500	shares
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	552000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1023000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	700000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	495000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	169000	USD
	iova	Payments For Legal Services PaymentsForLegalServices	400000	USD
	iova	Payments For Legal Services PaymentsForLegalServices	300000	USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	iova	Payments For Legal Services PaymentsForLegalServices	200000	USD
CY2016Q2	iova	Payments For Legal Services PaymentsForLegalServices	200000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2939000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><u><font style='FONT-FAMILY: "Times New Roman","serif"'>NOTE 8. LEGAL PROCEEDINGS</font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'"></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Class Action Lawsuits</u>. On April 10, 2017, the SEC announced settlements with us and with other public companies and unrelated parties in the <i>In the Matter of Certain Stock Promotion</i> investigation. Our settlement with the SEC is consistent with our previous disclosures (including in our Form 10-K that we filed with the SEC on March 9, 2017). On April 14 2017, a purported shareholder filed a class action complaint in the United States District Court, Northern District of California for violations of the federal securities laws (<i>Leonard DeSilvio v. Lion Biotechnologies, Inc., et al., case no: 3:17cv2086</i>) against our company and three of our former officers and directors. On April 19, 2017, a second class action complaint <i>(Amra Kuc vs. Lion Biotechnologies, Inc., et al., case no: 3:17cv2086</i>) was filed in the same court. Both complaints allege, among other things, that the defendants violated the federal securities laws by making materially false and misleading statements, or by failing to make certain disclosures, regarding the actions taken by Manish Singh and our former investor relations firm that were the subject of the <i>In the Matter of Certain Stock Promotions</i> SEC investigation. On July 20, 2017 the plaintiff in the <i>Kuc</i> case filed a notice to voluntarily dismiss that case. The Court entered an order dismissing the <i> Kuc</i> complaint on July 21, 2017. On July 26, 2017, the court appointed a movant as lead plaintiff. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"> </font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'">We intend to vigorously defend against the foregoing complaints. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'"> </font> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><u> Solomon Capital, LLC.</u> On April 8, 2016, a lawsuit titled <i> Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Lion Biotechnologies, Inc.</i> was filed by Solomon Capital, LLC, Solomon Capital 401(k) Trust, Solomon Sharbat and Shelhav Raff against the Company in the Supreme Court of the State of New York, County of New York (index no. 651881/2016). The plaintiffs allege that, between June and November 2012 they provided to the Company $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font> million and that they advanced and paid on our behalf an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million. The complaint further alleges that the Company agreed to (i) provide them with promissory notes totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million, plus interest, (ii) issue a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 111,425</font> shares to the plaintiffs (before the 1-for-100 reverse split of our common stock effected in September 2013), and (iii) allow the plaintiffs to convert the foregoing funds into our securities in the next transaction. The plaintiffs allege that they should have been able to convert their advances and payments into shares of the Company’s common stock in the restructuring that was effected in May 2013. Based on the foregoing, the plaintiffs allege causes for breach of contract and unjust enrichment and demand judgment against the Company in an unspecified amount exceeding $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million, plus interest and attorneys’ fees.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'">On June 3, 2016, the Company filed an answer and counterclaims in the lawsuit. In its counterclaims, the Company alleges that the plaintiffs misrepresented their qualifications to assist it in fundraising and that they failed to disclose that they were under investigation for securities laws violations. The Company is seeking damages in an amount exceeding $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.5</font> million and an order rescinding any and all agreements that the plaintiffs contend entitled them to obtain stock in the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"> </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'">On April 19, 2017, the Court granted plaintiffs’ counsel’s motion to withdraw from the case. On May 25, 2017, plaintiffs filed a notice that they had hired new counsel. On June 7, 2017, the judge presiding over the case recused herself because of a conflict of interest arising from her relationship with plaintiffs’ new attorneys.  The case has been assigned to a new judge, but the court has not yet scheduled a status conference or otherwise set a schedule for the case.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'">The Company intends to vigorously defend the complaint and pursue its counterclaims.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'">  </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><u>Other Matters.</u> During the second quarter of 2016, warrants representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 128,500</font> shares were exercised. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 128,500</font> shares of common stock had previously been registered for re-sale. However, we believe that these <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 128,500</font> warrant shares were sold by the holders in open market transactions in May 2016 at a time when the registration statement was ineffective. Accordingly, those sales were not made in accordance with Sections 5 and 10(a)(3) of the Securities Act, and the purchasers of those shares may have rescission rights (if they still own the shares) or claims for damages (if they no longer own the shares). The amount of any such liability is uncertain and as such, an accrual for any potential loss has not been made. The Company believes that any claims brought against it would not result in a material impact to the Company’s financial position or results of operations. The Company has not accrued a loss for a potential claim associated with this matter as it is unable to estimate any at this time.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'">The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36276000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8655000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10082000	USD
	us-gaap	Operating Expenses OperatingExpenses	44464000	USD
	us-gaap	Operating Expenses OperatingExpenses	18737000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44464000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18737000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	403000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	290000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8188000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44061000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62371	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49807	shares
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11553000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	95685000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62248074	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62680390	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62248074	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62680390	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation of short-term investments, accounting for potential liabilities, the valuation allowance associated with the Company’s deferred tax assets, and the assumptions made in valuing stock instruments issued for services.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Reclassifications</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Certain amounts within the statements of cash flows for the prior periods have been reclassified to conform with the current period presentation. These reclassifications had no impact on the Company's previously reported financial position or cash flows for any of the periods presented.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22245886	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24089088	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	6589000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	7136000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	500000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	30000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23379000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18417000	USD
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	3000000	USD
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	4600000	USD
CY2017Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2016Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.98
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.68

Files In Submission

Name	View Source	Status
0001144204-17-040380-index-headers.html	Edgar Link	pending
0001144204-17-040380-index.html	Edgar Link	pending
0001144204-17-040380.txt	Edgar Link	pending
0001144204-17-040380-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
iova-20170630.xml	Edgar Link	completed
iova-20170630.xsd	Edgar Link	pending
iova-20170630_cal.xml	Edgar Link	unprocessable
iova-20170630_def.xml	Edgar Link	unprocessable
iova-20170630_lab.xml	Edgar Link	unprocessable
iova-20170630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v471203_10q.htm	Edgar Link	pending
v471203_ex10-1.htm	Edgar Link	pending
v471203_ex31-1.htm	Edgar Link	pending
v471203_ex31-2.htm	Edgar Link	pending
v471203_ex32-1.htm	Edgar Link	pending
v471203_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2017 Q2 Form 10-Q Financial Statement

#000114420417040380 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2017 Q2 Form 10-Q Financial Statement

#000114420417040380 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova